Supply Security And Competitive Pricing Will Support Byooviz Launch In US
Samsung Bioepis And Biogen Executives Discuss Newly Introduced Lucentis Biosimilar
In the first part of an exclusive two-part interview, Samsung Bioepis’ development division leader Kyung-Ah Kim and Biogen’s global head of biosimilars Ian Henshaw discuss how the firms are aiming to capitalize on their launch of the world’s first Lucentis biosimilar, Byooviz, in the US.
